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Abstract 
Background: Available data from South Asia show one-third of TB deaths of the 
global burden. One-fifth among the treated cases had rifampicin-resistant TB.  Four 
oral anti-tuberculosis drugs have been conceived to be the most effective ones to 
eradicate this bacterium Mycobacterium tuberculosis and to obviate the resistance 
organism. Nonetheless, the patients' adherence and medication discrepancies are 
obstacles to achieving the goal. This study aims to define the anti-tuberculosis drug in 
the hospitals to detect the discrepancies and the continuity of the tuberculosis 
treatment. Methods: This retrospective cross-sectional study is based on the medical 
records of adult patients (17-65 years old) with a diagnosis of pulmonary tuberculosis 
and hospitalized with the ICD-X code A15.0 (verified using sputum microscopy with 
or without culture) between January and December 2018. From 136 and 85 patients' 
medical records that observed, only thirty-five records from Hospital A and thirty-
three records from Hospital B met the inclusion criteria. These two hospitals were a 
secondary care hospital with a total of 223 and 323 inpatient beds, respectively. 
Results: The most systemic anti-infective drugs were ceftriaxone (51.80 DDD/100 
bed days) in Hospital A and isoniazid (50.08 DDD/100 bed days) in Hospital B. The 
number of rifampicin was less than isoniazid. The number of anti-tuberculosis drugs 
was 108.8 DDD/100 bed days (52.6%) in Hospital A and 194.50 DDD/100 bed days 
(100%) in Hospital B.  Each patient received an average of 2 DDD/100 bed days. 
Conclusion: In the two-month intensive phase, each patient received four-drug fixed-
dose combination therapy and two-drug fixed-dose combination therapy in the four-
month continuation phase. The medication discrepancies will threaten the anti-
tuberculosis drug effectiveness. Thus, medication reconciliation is needed to 
accomplish the TB-free world in 2035. 
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